Hologic Inc.is slated to sell its profitable blood screening business, which accounted for almost 20 percent of the Marlborough, Mass. company's diagnostic revenues in fiscal 2016. The price is $1.85 billion in cash, which is much richer comparatively than other recent diagnostic acquisition comps, at least one Wall Street analyst noted. Read More
